Cochrane · systematic review · CD012381
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis
Davies, SC, Hussein, IM, Nguyen, TM, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 1 · 16.7%High 4 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tofacitinib compared to placebo for maintenance of remission in ulcerative colitis
Population: participants with quiescent ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to achieve clinical remission (5 mg/10 mg) Tofacitinib vs placebo | RR 0.7 [0.64, 0.77] | 1 study · 593 participants | High |
Failure to maintain clinical response (5 mg/10 mg) Tofacitinib vs placebo | RR 0.54 [0.47, 0.62] | 1 study · 593 participants | High |
Failure to achieve endoscopic remission (5 mg/10 mg) Tofacitinib vs placebo | RR 0.88 [0.83, 0.92] | 1 study · 593 participants | High |
Adverse events (5 mg/10 mg) Tofacitinib vs placebo | RR 1.01 [0.92, 1.11] | 1 study · 592 participants | High |
Serious adverse events (5 mg/10 mg) Tofacitinib vs placebo | RR 0.81 [0.42, 1.59] | 1 study · 592 participants | Low Downgraded: imprecision |
Withdrawals due to adverse events (5 mg/10 mg) Tofacitinib vs placebo | RR 0.5 [0.33, 0.77] | 1 study · 592 participants | Moderate Downgraded: imprecision |